GVT activity is enhanced in mESC-derived TEP-treated BM transplant recipients. Lethally irradiated C57BL/6 mice were injected intrathymically with mESC-derived EpCAM1⁺, EpCAM1⁻ cells, or PBS, and intravenously with 5 × 10⁶ TCD BM from BALB/c mice. At day 14 after BMT, the recipients were injected subcutaneously with B16F10 melanoma cells. (A) The mean tumor volume (in mm³) ± SD are shown. (B-D) At day 17 after tumor injection, single-cell suspensions from (B) the tumors were analyzed for CD4⁺ and CD8⁺ T cells (mean cell number/mg of tumor ± SD); (C) DLNs and (D) spleens were cultured with irradiated B16F10 melanoma or Lewis lung cancer cells. ELISPOT assays were then performed for IFN-γ⁺ cells. Mean number of spots/1 × 10⁵ T cells ± SD are presented (n = 5-6). **P < .01 and ***P < .001. The data are representative of 2 independent experiments.